Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
MINNEAPOLIS, Nov. 22, 2016 -- Lockridge Grindal Nauen P.L.L.P. announces that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NYSE:ALXN) securities between February 10, 2014 through November 9, 2016 (the “Class Period”).
If you are a member of the proposed Class, you may move the Court to serve as a lead plaintiff for the Class on or before January 17, 2017. You do not need to be a lead plaintiff in order to share in any recovery that may be obtained.
The Complaint alleges Alexion made false and/or misleading statements and/or failed to disclose: 1) that the Company employed improper sales practices with respect to its product Soliris; 2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and 3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times. On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. Following the cancellation, analysts noticed that the Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On this news, Alexion’s share price fell $8.95, or 6.94%, to close at $120.05 on November 7, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this information was disclosed, shares of Alexion declined in value, causing investors harm. On this news, Alexion’s share price fell $0.28, or 0.22%, to close at $126.88 on November 10, 2016. As the market continued to digest the significance of Alexion’s announced investigation, Alexion’s share price fell an additional $13.26, or 10.45%, to close at $113.62 on November 11, 2016.
If you purchased Alexion Pharmaceuticals, Inc. stock during the Class Period, or have any questions concerning this notice or your rights with respect to this matter, please contact:
Gregg M. Fishbein, Esq. ([email protected])
Lockridge Grindal Nauen P.L.L.P.
100 Washington Avenue South, Suite 2200
Minneapolis, MN 55401
(612) 339-6900
